

Receipt



Patent Application 10/706,555  
Attorney Docket No. PC27721

I hereby certify that this paper or fee is being deposited with the United States Postal Service as first class mail to Addressee" service under 37 CFR 1.10 on March 3, 2004 and is addressed to Commissioner for Patents, Customer Service Center, P.O. Box 1450, Alexandria, VA 22313-1450.

By

(Signature of person mailing)

Andrea E. Dorigo

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: John W. Mickelson :

APPLICATION NO.: 10/706,555 :

FILING DATE: November 12, 2003 :

TITLE: PYRAZINE COMPOUNDS AS CRF  
MODULATORS :

Commissioner for Patents  
Customer Service Center  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

**REQUEST FOR CORRECTED FILING RECEIPT**

Applicant requests that the Domestic Priority for the above identified application be corrected to read:

"Domestic Priority data as claimed by Applicant: U.S. Serial No. 60/428,146 filed November 12, 2003." A copy of the Filing Receipt with the above correction is attached.

Respectfully submitted,

Date: March 3, 2004

Andrea E. Dorigo  
Attorney for Applicant(s)  
Reg. No. 47,532

Pfizer, Inc  
Patent Department, 5th Floor  
150 East 42nd Street  
New York, NY 10017-5612  
(212) 733-7122



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/706,555	11/12/2003	1614	788	01346.US1		21	1

RC-2TT21

CONFIRMATION NO. 6894

25533  
PHARMACIA & UPJOHN  
301 HENRIETTA ST  
0228-32-LAW  
KALAMAZOO, MI 49007

## FILING RECEIPT



\*OC000000011860993\*

Date Mailed: 02/09/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

John W. Mickelson, Mattawan, MI;

## Domestic Priority data as claimed by applicant

## Foreign Applications

U.S. Ser. No.  
60/428,146 filed  
11/21/02

FEB 23 2004

If Required, Foreign Filing License Granted: 02/09/2004

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

## Title

Pyrazine compounds as CRF modulators

## Preliminary Class

514

RECEIVED

FEB 18 2004

PHARMACIA  
GLOBAL INTELLECTUAL PROPERTY

AE  
C

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).